Voyager Medical Research

Company Overview

Snapshot

Founded in August 2015 by Daniel Cohn and Ariel Halevy, Voyager Medical Research operates with 1–10 employees. The company has raised $1.5M across one funding round from one investor. In January 2019, the company secured funding from the Israel Innovation Authority.

Business overview

Voyager Medical Research develops proprietary polymers to prevent complications in abdominal wall surgery. Its primary product, Voyager Surgical Suture (VSS), is designed to address incisional hernia, a common post-surgical complication. The company's ACE Surgical Suture, a monofilament, absorbable surgical suture, offers extended abdominal wall support compared to competitor products, facilitating healing even in immune-suppressed patients. Voyager Medical Research operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering, serving hospitals, surgeons, and healthcare providers globally.

Company Intelligence Q&A

What is Voyager Medical Research's primary product?

Voyager Medical Research's primary product is Voyager Surgical Suture (VSS), a specialized suture designed to prevent incisional hernia after abdominal wall surgery.

When was Voyager Medical Research founded?

Voyager Medical Research was founded in August 2015.

Who are the co-founders of Voyager Medical Research?

Daniel Cohn and Ariel Halevy are the co-founders of Voyager Medical Research.

What is the key innovation of ACE Surgical Suture?

ACE Surgical Suture, developed by Voyager Medical Research, is based on a unique co-polymer (PPCA) that provides 5-6 months of abdominal wall support, significantly longer than competitor products, aiding healing for even immune-suppressed patients.

What is the latest funding information for Voyager Medical Research?

In January 2019, Voyager Medical Research secured funding from the Israel Innovation Authority.